Rapamycin serves as a primary intervention for extending health span, with low-dose applications showing potential to mitigate age-related decline in hearing, skin elasticity, and periodontal health. While currently FDA-approved for organ transplant recipients, its off-label use for longevity is gaining traction among individuals seeking to optimize biological aging. Beyond pharmacological approaches, the field of regenerative medicine faces significant regulatory barriers that stifle innovation and delay patient access to breakthrough therapies. Experts emphasize the necessity of political advocacy to reform these systems, mirroring historical movements that accelerated drug development for crises like HIV. Emerging gene therapies, particularly those utilizing viral vectors, offer a path toward long-term biological enhancement, though these remain experimental and largely confined to offshore clinical environments. The integration of lifestyle interventions alongside these emerging technologies remains the most immediate, actionable strategy for individuals pursuing longevity.
Sign in to continue reading, translating and more.
Open full episode in Podwise